<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04051957</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-19-0429</org_study_id>
    <nct_id>NCT04051957</nct_id>
  </id_info>
  <brief_title>Isosorbide Mononitrate For Anti-Vascular Endothelial Growth Factor (VEGF) Induced Kidney Injury</brief_title>
  <official_title>Isosorbide Mononitrate For Anti-Vascular Endothelial Growth Factor (VEGF) Induced Kidney Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Kidney Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the hypothesis that isosorbide mononitrate prevents
      deterioration of renal function in patients receiving anti-angiogenic therapies that target
      vascular endothelial growth factor (VEGF).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 26, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Double blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with a reduction in Urine Protein Creatinine ratio (UPC )of &gt; 500 mg/day from that measured before enrollment</measure>
    <time_frame>Baseline,Month 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with a reduction in UPC of &gt; 500 mg/day from that measured before enrollment</measure>
    <time_frame>Baseline,Month 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with a reduction in UPC of &gt; 500 mg/day from that measured before enrollment</measure>
    <time_frame>Baseline,Month 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with improvement in estimated Glomerular Filtration Rate (eGFR)≥25% from before enrollment</measure>
    <time_frame>Baseline,Month 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with improvement in estimated Glomerular Filtration Rate (eGFR)≥25% from before enrollment</measure>
    <time_frame>Baseline,Month 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with improvement in estimated Glomerular Filtration Rate (eGFR)≥25% from before enrollment</measure>
    <time_frame>Baseline,Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with reduction in systolic blood pressure (SBP) of ≥ 10 mm Hg and/or diastolic blood pressure (DBP) ≥ 5 mm Hg from before enrollment</measure>
    <time_frame>Baseline,Week 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with reduction in systolic blood pressure (SBP) of ≥ 10 mm Hg and/or diastolic blood pressure (DBP) ≥ 5 mm Hg from before enrollment</measure>
    <time_frame>Baseline,Week 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with reduction in systolic blood pressure (SBP) of ≥ 10 mm Hg and/or diastolic blood pressure (DBP) ≥ 5 mm Hg from before enrollment</measure>
    <time_frame>Baseline,Week 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with reduction in systolic blood pressure (SBP) of ≥ 10 mm Hg and/or diastolic blood pressure (DBP) ≥ 5 mm Hg from before enrollment</measure>
    <time_frame>Baseline,Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with reduction in systolic blood pressure (SBP) of ≥ 10 mm Hg and/or diastolic blood pressure (DBP) ≥ 5 mm Hg from before enrollment</measure>
    <time_frame>Baseline,Week 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with reduction in systolic blood pressure (SBP) of ≥ 10 mm Hg and/or diastolic blood pressure (DBP) ≥ 5 mm Hg from before enrollment</measure>
    <time_frame>Baseline,Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with reduction in systolic blood pressure (SBP) of ≥ 10 mm Hg and/or diastolic blood pressure (DBP) ≥ 5 mm Hg from before enrollment</measure>
    <time_frame>Baseline,Week 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with reduction in systolic blood pressure (SBP) of ≥ 10 mm Hg and/or diastolic blood pressure (DBP) ≥ 5 mm Hg from before enrollment</measure>
    <time_frame>Baseline,Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with reduction in systolic blood pressure (SBP) of ≥ 10 mm Hg and/or diastolic blood pressure (DBP) ≥ 5 mm Hg from before enrollment</measure>
    <time_frame>Baseline,Week 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with reduction in systolic blood pressure (SBP) of ≥ 10 mm Hg and/or diastolic blood pressure (DBP) ≥ 5 mm Hg from before enrollment</measure>
    <time_frame>Baseline,Week 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with reduction in systolic blood pressure (SBP) of ≥ 10 mm Hg and/or diastolic blood pressure (DBP) ≥ 5 mm Hg from before enrollment</measure>
    <time_frame>Baseline,Week 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with reduction in systolic blood pressure (SBP) of ≥ 10 mm Hg and/or diastolic blood pressure (DBP) ≥ 5 mm Hg from before enrollment</measure>
    <time_frame>Baseline,Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Kidney Injury</condition>
  <condition>Proteinuria</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Isosorbide Mononitrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isosorbide Mononitrate</intervention_name>
    <description>The starting dose will be Isosorbide Mononitrate 60 mg ER daily and after 4 weeks, if tolerated but response is not achieved, the dose will be escalated to Isosorbide Mononitrate 120 mg ER daily (2 tabs of 60 mg ER tablets).</description>
    <arm_group_label>Isosorbide Mononitrate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Placebo will be given daily and will be doubled after 4 weeks of start of therapy.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients on or enrolled for anti-VEGF therapy

          -  new-onset proteinuria, defined as a urine protein: creatinine ratio (UPC) of &gt;500mg/g
             or hypertension (Systolic BP ≥ 140 mm Hg and/or diastolic BP ≥ 90 mm Hg) or a decrease
             in eGFR by ≥ 25% from baseline before starting therapy.

        Exclusion Criteria:

          -  Pregnant women

          -  Breast-feeding women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaya Kala, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jaya Kala, MD</last_name>
    <phone>7135006868</phone>
    <email>jaya.kala@uth.tmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Iram Abbasi</last_name>
    <phone>7135006820</phone>
    <email>iram.s.abbasi@uth.tmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The University Of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaya Kala, MD</last_name>
      <phone>713-500-6868</phone>
      <email>jaya.kala@uth.tmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Iram Abbasi</last_name>
      <phone>7135006820</phone>
      <email>iram.s.abbasi@uth.tmc.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 7, 2019</study_first_submitted>
  <study_first_submitted_qc>August 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2019</study_first_posted>
  <last_update_submitted>September 24, 2019</last_update_submitted>
  <last_update_submitted_qc>September 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Jaya Kala</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Kidney Injury</keyword>
  <keyword>Proteinuria</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Anti-VEGF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Proteinuria</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isosorbide</mesh_term>
    <mesh_term>Isosorbide Dinitrate</mesh_term>
    <mesh_term>Isosorbide-5-mononitrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

